|
Alpelisib Clinical Trials
6 actively recruiting trials across 4 locations
▼ -1 trial since August 2026
Also known as: BYL 719, BYL-719, BYL719, PI3K Inhibitor, PIQRAY® +3 more
Pipeline
Phase 2: 4Phase 3: 1Phase 2/3: 1
Top Sponsors
- The Netherlands Cancer Institute1
- Novartis Pharmaceuticals1
- National Cancer Institute (NCI)1
- Murdoch Childrens Research Institute1
- Hoffmann-La Roche1
Indications
- Cancer6
- Breast Cancer3
- Unresectable HER2-Negative Breast Carcinoma1
- Arteriovenous Malformation (AVM)1
- MAP2K1 Gene Mutation1
Other2 trials
Birmingham, Alabama1 trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
University of Alabama at Birmingham Cancer Center
Phase 2
Greenbrae, California1 trial
Oakland, California1 trial
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
UCSF Benioff Children s Hospital
Phase 2/3
Lebanon, New Hampshire1 trial
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Dartmouth Hitchcock Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.